Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Up 2,372,871.6% in April

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 5,006,970 shares, a growth of 2,372,871.6% from the March 31st total of 211 shares. Based on an average trading volume of 51,096,171 shares, the days-to-cover ratio is presently 0.1 days. Currently, 210.0% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and set a $1.00 price objective (down from $3.00) on shares of Virax Biolabs Group in a research note on Friday, January 9th. Zacks Research upgraded shares of Virax Biolabs Group to a “hold” rating in a research note on Tuesday, January 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Virax Biolabs Group in a research note on Wednesday, April 8th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Virax Biolabs Group has a consensus rating of “Hold” and a consensus price target of $1.00.

Virax Biolabs Group Price Performance

Shares of NASDAQ:VRAX opened at $0.16 on Friday. Virax Biolabs Group has a 1-year low of $0.10 and a 1-year high of $1.20. The company’s fifty day moving average is $0.18 and its two-hundred day moving average is $0.34.

Virax Biolabs Group Company Profile

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.